Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system.
Identifieur interne : 000096 ( PubMed/Corpus ); précédent : 000095; suivant : 000097Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system.
Auteurs : Roger Loria ; Mathew Beckman ; Daniel Contaifer ; Francisco Tamariz ; David Gibb ; Laura Thompson ; Peter GuidaSource :
- Cancer biotherapy & radiopharmaceuticals [ 1557-8852 ] ; 2011.
English descriptors
- KwdEn :
- Androstenediol (pharmacology), Animals, Bone Marrow (drug effects), Bone Marrow (radiation effects), Bone Marrow Cells (drug effects), Bone Marrow Cells (radiation effects), Flow Cytometry, Heavy Ions (adverse effects), Hematopoietic System (drug effects), Hematopoietic System (radiation effects), Injections, Subcutaneous, Iron (chemistry), Male, Mice, Mice, Inbred C57BL, Osteoclasts (cytology), Osteoclasts (drug effects), Osteoclasts (radiation effects), Radiation Injuries, Experimental (etiology), Radiation Injuries, Experimental (prevention & control), Radiation-Protective Agents (pharmacology), Whole-Body Irradiation.
- MESH :
- chemical , chemistry : Iron.
- chemical , pharmacology : Androstenediol, Radiation-Protective Agents.
- adverse effects : Heavy Ions.
- cytology : Osteoclasts.
- drug effects : Bone Marrow, Bone Marrow Cells, Hematopoietic System, Osteoclasts.
- etiology : Radiation Injuries, Experimental.
- prevention & control : Radiation Injuries, Experimental.
- radiation effects : Bone Marrow, Bone Marrow Cells, Hematopoietic System, Osteoclasts.
- Animals, Flow Cytometry, Injections, Subcutaneous, Male, Mice, Mice, Inbred C57BL, Whole-Body Irradiation.
Abstract
Space exploration is associated with exposure to 1-3 Gy solar particle radiation and galactic cosmic radiation that could increase cancer rates. Effective nontoxic countermeasures to high linear energy transfer (LET) radiation exposure are highly desirable but currently not available. The aim was to determine whether a single subcutaneous injection of androstenediol (Δ(5) androsten-3β, 17β-diol [AED]) could mitigate and restore the mouse hematopoetic system from the radiation-mediated injury of 3 Gy whole-body high LET (56)Fe(26+) exposure. The findings show that postradiation AED treatment has an overall positive and significant beneficial effect to restore the levels of hematopoeitic elements (p<0.001). Androstenediol treatment significantly increased monocyte levels at days 4, 7, and 14 and, similarly, increased red blood cell, hemoglobin, and platelet counts. Flow cytometry analysis 14 days after radiation and AED treatment demonstrated an increase (p<0.05) in bone marrow cells counts. Ex vivo osteoclastogenesis studies show that AED treatment is necessary and advantageous for the development and restoration of osteoclastogenesis after radiation exposure. These findings clearly show that androstenediol functions as a countermeasure to remedy hematopoeitic injury mediated by high LET iron ion radiation. Presently, no other agent has been shown to have such properties.
DOI: 10.1089/cbr.2010.0907
PubMed: 21790310
Links to Exploration step
pubmed:21790310Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system.</title><author><name sortKey="Loria, Roger" sort="Loria, Roger" uniqKey="Loria R" first="Roger" last="Loria">Roger Loria</name><affiliation><nlm:affiliation>Department of Microbiology, Immunology, Virginia Commonwealth University, 1101 E. Marshal Street, Richmond, VA 23298-0678, USA. loria@vcu.edu</nlm:affiliation></affiliation></author><author><name sortKey="Beckman, Mathew" sort="Beckman, Mathew" uniqKey="Beckman M" first="Mathew" last="Beckman">Mathew Beckman</name></author><author><name sortKey="Contaifer, Daniel" sort="Contaifer, Daniel" uniqKey="Contaifer D" first="Daniel" last="Contaifer">Daniel Contaifer</name></author><author><name sortKey="Tamariz, Francisco" sort="Tamariz, Francisco" uniqKey="Tamariz F" first="Francisco" last="Tamariz">Francisco Tamariz</name></author><author><name sortKey="Gibb, David" sort="Gibb, David" uniqKey="Gibb D" first="David" last="Gibb">David Gibb</name></author><author><name sortKey="Thompson, Laura" sort="Thompson, Laura" uniqKey="Thompson L" first="Laura" last="Thompson">Laura Thompson</name></author><author><name sortKey="Guida, Peter" sort="Guida, Peter" uniqKey="Guida P" first="Peter" last="Guida">Peter Guida</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1089/cbr.2010.0907</idno><idno type="RBID">pubmed:21790310</idno><idno type="pmid">21790310</idno><idno type="wicri:Area/PubMed/Corpus">000096</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000096</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system.</title><author><name sortKey="Loria, Roger" sort="Loria, Roger" uniqKey="Loria R" first="Roger" last="Loria">Roger Loria</name><affiliation><nlm:affiliation>Department of Microbiology, Immunology, Virginia Commonwealth University, 1101 E. Marshal Street, Richmond, VA 23298-0678, USA. loria@vcu.edu</nlm:affiliation></affiliation></author><author><name sortKey="Beckman, Mathew" sort="Beckman, Mathew" uniqKey="Beckman M" first="Mathew" last="Beckman">Mathew Beckman</name></author><author><name sortKey="Contaifer, Daniel" sort="Contaifer, Daniel" uniqKey="Contaifer D" first="Daniel" last="Contaifer">Daniel Contaifer</name></author><author><name sortKey="Tamariz, Francisco" sort="Tamariz, Francisco" uniqKey="Tamariz F" first="Francisco" last="Tamariz">Francisco Tamariz</name></author><author><name sortKey="Gibb, David" sort="Gibb, David" uniqKey="Gibb D" first="David" last="Gibb">David Gibb</name></author><author><name sortKey="Thompson, Laura" sort="Thompson, Laura" uniqKey="Thompson L" first="Laura" last="Thompson">Laura Thompson</name></author><author><name sortKey="Guida, Peter" sort="Guida, Peter" uniqKey="Guida P" first="Peter" last="Guida">Peter Guida</name></author></analytic><series><title level="j">Cancer biotherapy & radiopharmaceuticals</title><idno type="eISSN">1557-8852</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Androstenediol (pharmacology)</term><term>Animals</term><term>Bone Marrow (drug effects)</term><term>Bone Marrow (radiation effects)</term><term>Bone Marrow Cells (drug effects)</term><term>Bone Marrow Cells (radiation effects)</term><term>Flow Cytometry</term><term>Heavy Ions (adverse effects)</term><term>Hematopoietic System (drug effects)</term><term>Hematopoietic System (radiation effects)</term><term>Injections, Subcutaneous</term><term>Iron (chemistry)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Osteoclasts (cytology)</term><term>Osteoclasts (drug effects)</term><term>Osteoclasts (radiation effects)</term><term>Radiation Injuries, Experimental (etiology)</term><term>Radiation Injuries, Experimental (prevention & control)</term><term>Radiation-Protective Agents (pharmacology)</term><term>Whole-Body Irradiation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Iron</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Androstenediol</term><term>Radiation-Protective Agents</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Heavy Ions</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Osteoclasts</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Marrow</term><term>Bone Marrow Cells</term><term>Hematopoietic System</term><term>Osteoclasts</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Radiation Injuries, Experimental</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Radiation Injuries, Experimental</term></keywords><keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Bone Marrow</term><term>Bone Marrow Cells</term><term>Hematopoietic System</term><term>Osteoclasts</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Flow Cytometry</term><term>Injections, Subcutaneous</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Whole-Body Irradiation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Space exploration is associated with exposure to 1-3 Gy solar particle radiation and galactic cosmic radiation that could increase cancer rates. Effective nontoxic countermeasures to high linear energy transfer (LET) radiation exposure are highly desirable but currently not available. The aim was to determine whether a single subcutaneous injection of androstenediol (Δ(5) androsten-3β, 17β-diol [AED]) could mitigate and restore the mouse hematopoetic system from the radiation-mediated injury of 3 Gy whole-body high LET (56)Fe(26+) exposure. The findings show that postradiation AED treatment has an overall positive and significant beneficial effect to restore the levels of hematopoeitic elements (p<0.001). Androstenediol treatment significantly increased monocyte levels at days 4, 7, and 14 and, similarly, increased red blood cell, hemoglobin, and platelet counts. Flow cytometry analysis 14 days after radiation and AED treatment demonstrated an increase (p<0.05) in bone marrow cells counts. Ex vivo osteoclastogenesis studies show that AED treatment is necessary and advantageous for the development and restoration of osteoclastogenesis after radiation exposure. These findings clearly show that androstenediol functions as a countermeasure to remedy hematopoeitic injury mediated by high LET iron ion radiation. Presently, no other agent has been shown to have such properties.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21790310</PMID><DateCreated><Year>2011</Year><Month>08</Month><Day>12</Day></DateCreated><DateCompleted><Year>2012</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2015</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8852</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cancer biotherapy & radiopharmaceuticals</Title><ISOAbbreviation>Cancer Biother. Radiopharm.</ISOAbbreviation></Journal><ArticleTitle>Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system.</ArticleTitle><Pagination><MedlinePgn>453-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/cbr.2010.0907</ELocationID><Abstract><AbstractText>Space exploration is associated with exposure to 1-3 Gy solar particle radiation and galactic cosmic radiation that could increase cancer rates. Effective nontoxic countermeasures to high linear energy transfer (LET) radiation exposure are highly desirable but currently not available. The aim was to determine whether a single subcutaneous injection of androstenediol (Δ(5) androsten-3β, 17β-diol [AED]) could mitigate and restore the mouse hematopoetic system from the radiation-mediated injury of 3 Gy whole-body high LET (56)Fe(26+) exposure. The findings show that postradiation AED treatment has an overall positive and significant beneficial effect to restore the levels of hematopoeitic elements (p<0.001). Androstenediol treatment significantly increased monocyte levels at days 4, 7, and 14 and, similarly, increased red blood cell, hemoglobin, and platelet counts. Flow cytometry analysis 14 days after radiation and AED treatment demonstrated an increase (p<0.05) in bone marrow cells counts. Ex vivo osteoclastogenesis studies show that AED treatment is necessary and advantageous for the development and restoration of osteoclastogenesis after radiation exposure. These findings clearly show that androstenediol functions as a countermeasure to remedy hematopoeitic injury mediated by high LET iron ion radiation. Presently, no other agent has been shown to have such properties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loria</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, Virginia Commonwealth University, 1101 E. Marshal Street, Richmond, VA 23298-0678, USA. loria@vcu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckman</LastName><ForeName>Mathew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Contaifer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tamariz</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gibb</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Guida</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA16059</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Biother Radiopharm</MedlineTA><NlmUniqueID>9605408</NlmUniqueID><ISSNLinking>1084-9785</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011837">Radiation-Protective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>95PS51EMXY</RegistryNumber><NameOfSubstance UI="D015114">Androstenediol</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>In Vivo. 2006 Nov-Dec;20(6B):781-9</RefSource><PMID Version="1">17203768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2006 May;7(5):431-5</RefSource><PMID Version="1">16648048</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Biol. 2008 Jul;84(7):549-59</RefSource><PMID Version="1">18661371</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiat Res. 2008 Sep;170(3):388-92</RefSource><PMID Version="1">18763868</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiat Environ Biophys. 2010 Aug;49(3):303-16</RefSource><PMID Version="1">20035342</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2000;917:860-7</RefSource><PMID Version="1">11268417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Lett. 2002 Jan 1;80(1):55-66</RefSource><PMID Version="1">11716966</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Lett. 2002 Jan 1;80(1):67-73</RefSource><PMID Version="1">11716967</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Orthop Res. 2002 Mar;20(2):174-81</RefSource><PMID Version="1">11918294</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Steroids. 2002 Nov;67(12):953-66</RefSource><PMID Version="1">12398992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Oncol. 2002 Dec;29(6 Suppl 19):9-13</RefSource><PMID Version="1">12577237</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomed Sci Instrum. 2004;40:99-104</RefSource><PMID Version="1">15133942</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lab Invest. 1985 Jul;53(1):72-9</RefSource><PMID Version="1">4010232</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1987 Nov 25;262(33):15922-9</RefSource><PMID Version="1">3680233</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Virol. 1992;127(1-4):103-15</RefSource><PMID Version="1">1456887</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Artif Organs. 1993 Nov;16(11):765-70</RefSource><PMID Version="1">8150522</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuroimmunol. 1997 Sep;78(1-2):203-11</RefSource><PMID Version="1">9307246</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 1998 Apr 17;93(2):165-76</RefSource><PMID Version="1">9568710</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuroimmunol. 1998 Apr 1;84(1):61-8</RefSource><PMID Version="1">9600709</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1998 Nov 6;273(45):29417-23</RefSource><PMID Version="1">9792645</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5</RefSource><PMID Version="1">10097072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Microbiol. 1999 May;48(5):425-31</RefSource><PMID Version="1">10229539</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Cell Biol. 1998;76(6):911-22</RefSource><PMID Version="1">10392705</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiat Res. 2006 Jan;165(1):68-77</RefSource><PMID Version="1">16392964</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiat Res. 2006 Jan;165(1):78-87</RefSource><PMID Version="1">16392965</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Biotechnol. 2006 Mar;24(3):131-6</RefSource><PMID Version="1">16460819</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):223-9</RefSource><PMID Version="1">18513951</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015114">Androstenediol</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001853">Bone Marrow</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001854">Bone Marrow Cells</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020450">Heavy Ions</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006413">Hematopoietic System</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000528">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007279">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007501">Iron</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010010">Osteoclasts</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011833">Radiation Injuries, Experimental</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011837">Radiation-Protective Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014916">Whole-Body Irradiation</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3192055</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1089/cbr.2010.0907</ArticleId><ArticleId IdType="pubmed">21790310</ArticleId><ArticleId IdType="pmc">PMC3192055</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000096 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000096 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21790310
|texte= Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21790310" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a InforLorV4
| This area was generated with Dilib version V0.6.33. |  |